News & Updates

The most effective nonsteroidal anti-inflammatory drugs (NSAIDs) for pain and function in patients with osteoarthritis (OA) are etoricoxib 60 mg/day and diclofenac 150 mg/day, suggests a study. However, these medications may not be suitable for those with comorbidities or for long-term use due to the slight increase in the risk of adverse events.

Cancer patients receiving either low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) show comparable frequency of venous thromboembolism (VTE), reports a recent study.

In the treatment of patients with severe, uncontrolled asthma, use of tezepelumab appears to produce rapid and sustained improvements in lung function, as reported in a study.

A 3-day course of remdesivir may help stave off COVID-19–related hospitalization and death, according to results of the phase III PINETREE study.

An ocular implant that continuously dispenses an antivascular endothelial growth factor (anti-VEGF) therapy into the vitreous performs well in the management of neovascular age-related macular degeneration, affording disease control and achieving vision and anatomical outcomes similar to that obtained with monthly intravitreal injections, as shown in the phase III ARCHWAY trial.

The combination of aspirin and warfarin therapy appears to increase the risk of bleeding, with little benefit in reducing stroke or cardiovascular events compared with warfarin alone in patients with atrial fibrillation (AF), reveals a study.

Hospitalized patients with COVID-19 who receive antiplatelet and anticoagulant drugs concurrently may fare better than those given only therapeutic anticoagulation, according to a study.